Lesopitron
Identification
- Generic Name
- Lesopitron
- DrugBank Accession Number
- DB04970
- Background
Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 320.82
Monoisotopic: 320.151622409 - Chemical Formula
- C15H21ClN6
- Synonyms
- 2-(4-(4-(4-Chloropyrazol-1-yl)butyl)-1-piperazinyl)pyrimidine
- Lesopitron
- External IDs
- E-4424
Pharmacology
- Indication
Intended for the treatment of anxiety disorders.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
In phase I trials in healthy volunteers, lesopitron was well tolerated in single doses up to 50 mg, and up to 45 mg/day in repeated doses. Lesopitron has negligible effects on alpha-adrenergic and dopaminergic receptors, and was more potent than structurally-related 5-HT1A agonists in rat social interaction and marmoset anxiety models. It also countered benzodiazepine withdrawal-induced anxiety in rodents. The acute toxicity of lesopitron is low and it does not potentiate the effects of alcohol or barbiturates. Long-term usage led to reductions in plasma glucose, triglycerides, phospholipids and cholesterol.
- Mechanism of action
Lesopitron acts as a ligand for central serotonin 5-HT1A receptors. Lesopitron inhibits haloperidol-induced catalepsy that is the consequence of its action on 5-HT1A autoreceptors. The ability of lesopitron to induce 5-HT syndrome reflects post-synaptic 5-HT1A receptor activation and the reversion of 8-OHDPAT-induced 5-HT syndrome by lesopitron suggests a partial agonist effect on this receptor-type. Lesopitron induced a hypothermic effect due to the enhanced activation of post-synaptic 5-HT1A receptors. The agonist effect of lesopitron on 5-HT1A receptors and its marked hypothermic effect is an added value for this drug and a stimulus to the study of its possible neuroprotective action.
Target Actions Organism U5-hydroxytryptamine receptor 1A Not Available Humans - Absorption
Rapidly absorbed in patients, having a time to maximum concentration (Tmax) ranging from 0.5 to 1 hour. The absolute bioavailability of lesopitron in rats was about 10%, suggesting an important first-pass effect.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hepatic, the main metabolite being 5-hydroxylesopitron.
- Route of elimination
Not Available
- Half-life
1.1 to 5.6 hours
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
The most commonly reported adverse events in all the panels in one study were headache, dizziness, and nausea [PMID: 8959472].
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Dialkylarylamines / N-alkylpiperazines / Aminopyrimidines and derivatives / Aryl chlorides / Pyrazoles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides show 1 more
- Substituents
- Amine / Aminopyrimidine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Azole / Dialkylarylamine / Heteroaromatic compound / Hydrocarbon derivative show 11 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- H1CGM4755H
- CAS number
- 132449-46-8
- InChI Key
- AHCPKWJUALHOPH-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H21ClN6/c16-14-12-19-22(13-14)7-2-1-6-20-8-10-21(11-9-20)15-17-4-3-5-18-15/h3-5,12-13H,1-2,6-11H2
- IUPAC Name
- 2-{4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine
- SMILES
- ClC1=CN(CCCCN2CCN(CC2)C2=NC=CC=N2)N=C1
References
- General References
- Fisas MA, Farre A, Camarasa J, Escubedo E: Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors. Pharmacology. 2004 Oct;72(2):57-67. [Article]
- Sramek JJ, Fresquet A, Marion-Landais G, Hourani J, Jhee SS, Martinez L, Jensen CM, Bolles K, Carrington AT, Cutler NR: Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol. 1996 Dec;16(6):454-8. [Article]
- Serafini MT, Puig S, Garcia-Encina G, Farran R, Garcia-Soret A, Moragon T, Martinez L: Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs. Methods Find Exp Clin Pharmacol. 1997 Jan-Feb;19(1):61-72. [Article]
- Micheli F: Lesopitron (Esteve). IDrugs. 2001 Feb;4(2):218-24. [Article]
- External Links
- PubChem Compound
- 60813
- PubChem Substance
- 175426922
- ChemSpider
- 54801
- BindingDB
- 82365
- ChEMBL
- CHEMBL2105051
- ZINC
- ZINC000001547604
- Wikipedia
- Lesopitron
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.25 mg/mL ALOGPS logP 2.64 ALOGPS logP 2.09 Chemaxon logS -2.4 ALOGPS pKa (Strongest Basic) 7.74 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 50.08 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 100.45 m3·mol-1 Chemaxon Polarizability 34.99 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9388 Caco-2 permeable + 0.5377 P-glycoprotein substrate Substrate 0.5064 P-glycoprotein inhibitor I Non-inhibitor 0.5352 P-glycoprotein inhibitor II Inhibitor 0.5325 Renal organic cation transporter Inhibitor 0.8173 CYP450 2C9 substrate Non-substrate 0.8939 CYP450 2D6 substrate Non-substrate 0.727 CYP450 3A4 substrate Non-substrate 0.5 CYP450 1A2 substrate Inhibitor 0.9287 CYP450 2C9 inhibitor Inhibitor 0.5 CYP450 2D6 inhibitor Non-inhibitor 0.6038 CYP450 2C19 inhibitor Inhibitor 0.8001 CYP450 3A4 inhibitor Non-inhibitor 0.8805 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8893 Ames test Non AMES toxic 0.665 Carcinogenicity Non-carcinogens 0.8502 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6276 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.8734 hERG inhibition (predictor II) Inhibitor 0.6537
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-03fr-2910000000-0ff79ee3f0ac3ab5b8c3 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0019000000-d0b7a7f836410238a1e9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0039000000-a61f3d6f7dd57f64daed Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0191000000-365573f0f3a70d078217 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-2092000000-4d1691a71984dff7f82f Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0f96-0290000000-e1a7e753e6e0bb10afea Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0f8c-6390000000-ae876eb28edda17800d7 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.53908 predictedDeepCCS 1.0 (2019) [M+H]+ 175.89708 predictedDeepCCS 1.0 (2019) [M+Na]+ 181.99025 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serotonin receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
- Gene Name
- HTR1A
- Uniprot ID
- P08908
- Uniprot Name
- 5-hydroxytryptamine receptor 1A
- Molecular Weight
- 46106.335 Da
References
Drug created at October 21, 2007 22:23 / Updated at February 21, 2021 18:51